- Home
- EQR vs BIIB Comparison
EQR vs BIIB Comparison
Compare EQR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQR | BIIB |
|---|---|---|
| Founded | 1993 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 24.2B |
| IPO Year | 1993 | 1991 |
Fundamental Metrics
Financial Performance| Metric | EQR | BIIB |
|---|---|---|
| Price | $60.93 | $174.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 22 |
| Target Price | $70.00 | ★ $177.40 |
| AVG Volume (30 Days) | ★ 2.0M | 2.0M |
| Earning Date | 02-02-2026 | 10-30-2025 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | ★ 24.49 | N/A |
| EPS | 3.03 | ★ 10.97 |
| Revenue | $3,078,827,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $5.06 | $3.61 |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | $20.09 | ★ $15.86 |
| Revenue Growth | 4.69 | ★ 4.77 |
| 52 Week Low | $58.38 | $110.04 |
| 52 Week High | $75.86 | $185.17 |
Technical Indicators
Market Signals| Indicator | EQR | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 55.41 |
| Support Level | $60.01 | $169.24 |
| Resistance Level | $61.39 | $180.79 |
| Average True Range (ATR) | 0.95 | 5.36 |
| MACD | 0.02 | -1.56 |
| Stochastic Oscillator | 39.09 | 33.70 |
Price Performance
Historical ComparisonAbout EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).